Non-interventional Prospective Data Collection on Persistence and Adherence on Ticagrelor in ACS Adult Patients in Serbia
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 Oct 2018
At a glance
- Drugs Ticagrelor (Primary)
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- Acronyms ADHERE-S (NIS Brilique)
- Sponsors AstraZeneca
- 04 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Sep 2018 Planned End Date changed from 30 Jun 2019 to 30 Sep 2019.
- 18 Sep 2018 Planned primary completion date changed from 30 Jun 2019 to 30 Sep 2019.